logo
logo

Occamzrazor Announces Closing Of $6.1M Financing Round To Launch Their Ai-Enabled Discovery Pipeline And Advance Preclinical Development In Parkinson's.

Mar 08, 2022•over 3 years ago

Amount Raised

$6.1 Million

Description

OccamzRazor is on a mission to create the first curative treatments for complex brain-aging diseases, such as Parkinson's disease. The company recently received approximately $6.1M in financing to launch their AI-enabled discovery pipeline and advance preclinical development in Parkinson's. This round was led by Jeff Dean, one of the top AI researchers in modern machine learning today. Other investors include Lauder Partners, re.Mind Capital, and Valor Equity Partners.

Company Information

Company

Occamz Razor

About

The company recently received approximately $6.1M in financing to launch their AI-enabled discovery pipeline and advance preclinical development in Parkinson's. OccamzRazor was founded to help patients with brain-aging disorders where there is a lack of treatment options that halt or reverse the disease. OccamzRazor is on a mission to create the first curative treatments for complex brain-aging diseases, such as Parkinson's disease. OccamzRazor is determined to change this.